Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Theralase Technologies Inc
(OP:
TLTFF
)
0.1785
-0.0015 (-0.83%)
Streaming Delayed Price
Updated: 12:55 PM EST, Feb 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10,611
Open
0.1800
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1800
Today's Range
0.1785 - 0.1800
52wk Range
0.0800 - 0.2700
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
February 25, 2025
Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...
Via
Newsfile
Topics
Death
Exposures
Death
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
February 13, 2025
Via
ACCESS Newswire
Performance
YTD
-6.35%
-6.35%
1 Month
-9.57%
-9.57%
3 Month
+8.18%
+8.18%
6 Month
+37.41%
+37.41%
1 Year
+11.01%
+11.01%
More News
Read More
Theralase(R) Demonstrates Effective Treatment of Herpes
February 12, 2025
Via
ACCESS Newswire
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
February 10, 2025
Via
ACCESS Newswire
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
January 27, 2025
Via
ACCESS Newswire
Theralase(R) Launches New Clinical Study Site in Canada
December 05, 2024
Via
ACCESSWIRE
Theralase(R) Launches Three New Clinical Study Sites in USA
December 09, 2024
Via
ACCESSWIRE
Theralase(R) Release’s 3Q2024 Financial Statements
November 27, 2024
Via
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement
November 15, 2024
Via
ACCESSWIRE
Theralase(R) Extends Warrants
November 12, 2024
Via
ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 07, 2024
Via
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
September 24, 2024
Via
ACCESSWIRE
Theralase(R) Extends Warrants
September 19, 2024
Via
ACCESSWIRE
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
September 03, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
August 28, 2024
Via
ACCESSWIRE
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
August 21, 2024
Via
ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
August 12, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
July 08, 2024
Via
ACCESSWIRE
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
June 20, 2024
Via
ACCESSWIRE
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
June 19, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
June 18, 2024
Via
ACCESSWIRE
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
June 14, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy
June 12, 2024
Via
ACCESSWIRE
Ruvidar(TM) Enhances Efficacy of Cancer Drug
June 10, 2024
Via
ACCESSWIRE
Theralase(R) Successfully Destroys Lung Cancer
June 06, 2024
Via
ACCESSWIRE
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.